Copyright
©The Author(s) 2016.
World J Hepatol. Dec 18, 2016; 8(35): 1557-1563
Published online Dec 18, 2016. doi: 10.4254/wjh.v8.i35.1557
Published online Dec 18, 2016. doi: 10.4254/wjh.v8.i35.1557
Table 1 Patient characteristics (n = 60)
| Male (n = 38) | 63.3% |
| Female (n = 22) | 36.7% |
| Race | |
| Caucasian (n = 16) | 26.7% |
| African American (n = 25) | 41.7% |
| Hispanic (n = 3) | 5.0% |
| Asian (n = 2) | 3.3% |
| Not listed (n = 14) | 23.3% |
| Mean age ± SD | 60.6 ± 6.7 |
| Diabetic (n = 23) | 38.3% |
| Hyperlipidemia (n = 20) | 33.3% |
| Hypertension (n = 42) | 70.0% |
| Treatment | |
| Sofosbuvir/ribavarin/interferon (n = 21) | 35.0% |
| Sofosbuvir/simeprevir (n = 11) | 18.3% |
| Sofosbuvir/ledipesvir (n = 23) | 38.3% |
| Sofosbuvir/ribavirin (n = 4) | 8.3% |
| Sofosbuvir (n = 1) | 1.7% |
| Biopsy stage (n = 49) | |
| 1 (n = 8) | 13.3% |
| 2 (n = 21) | 35.0% |
| 3 (n = 5) | 8.3% |
| 4 (n = 15) | 25.0% |
| Statin use (n = 20) | 20.0% |
| Statin held during tx (n = 3) | 5.0% |
| Mean viral load | 4746471 ± 7641768 |
| Mean ALT | 72.1 ± 56.2 |
| Genotype | |
| 1a (n = 30) | 50.0% |
| 1b (n = 16) | 26.7% |
| 1 undistinguished (n = 9) | 15.0% |
| 2 (n = 2) | 3.3% |
| 3 (n = 3) | 5.0% |
- Citation: Morales AL, Junga Z, Singla MB, Sjogren M, Torres D. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol 2016; 8(35): 1557-1563
- URL: https://www.wjgnet.com/1948-5182/full/v8/i35/1557.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i35.1557